How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Anakinra Market
- By Indication: Rheumatoid Arthritis, Cryopyrin-Associated Periodic Syndromes (CAPS), Systemic Juvenile Idiopathic Arthritis (SJIA), Adult-Onset Still's Disease, Gout Flare
- By Route of Administration: Subcutaneous Injection
- By End User: Hospitals, Specialty Clinics, Ambulatory Care Centers
- By Dosage Strength: 100 mg Syringe, 150 mg Syringe
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Rheumatoid Arthritis leads By Indication at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 10 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 249 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.155 →
- 11 Company Profiles 10 players: SWOT & benchmarking p.163 →
Full report · locked preview
Everything inside the Anakinra Market report
A complete, evidence-based study - 11 chapters and 104 sections covering market size, segmentation across 4 axes, regional analysis and 10 company profiles, forecast to 2033.
Segmentation covered
Indication 5
Route of Administration 1
End User 3
Dosage Strength 2
Companies profiled
Swedish Orphan Biovitrum AB (Sobi)
Amgen Inc.
Horizon Therapeutics plc
Sandoz (a Novartis division)
Mylan N.V. (now part of Viatris)
Pfizer Inc.
AbbVie Inc.
Roche Holding AG
Sanofi S.A.
Bristol-Myers Squibb Company
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
10 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Swedish Orphan Biovitrum AB (Sobi)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Amgen Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Horizon Therapeutics plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Sandoz (a Novartis division)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Mylan N.V. (now part of Viatris)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.178 →Pfizer Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.184 →AbbVie Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Roche Holding AG
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Sanofi S.A.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.202 →Bristol-Myers Squibb Company
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.209 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$6,606M by 2033 · 10.8% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Rheumatoid Arthritis57.6
- Cryopyrin-Associated Periodic Syndromes (CAPS)7.9
- Systemic Juvenile Idiopathic Arthritis (SJIA)12.3
- Adult-Onset Still's Disease14.9
- Gout Flare7.4
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$956.6M → $2,134M · 10.6%
Europe$666.7M → $1,372M · 9.4%
Asia Pacific$608.8M → $1,434M · 11.3%
Latin America$376.9M → $849.5M · 10.7%
Middle East and Africa$289.9M → $713.3M · 11.9%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →10.802026
10.822027
10.812028
10.842029
10.842030
10.862031
10.872032
10.892033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Swedish Orphan Biovitrum AB (Sobi)14.8
- Amgen Inc.24.4
- Horizon Therapeutics plc4.6
- Sandoz (a Novartis division)9.6
- Mylan N.V. (now part of Viatris)8.4
- Pfizer Inc.10.1
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Indication24.4%
Route of Administration29.8%
End User16.0%
Dosage Strength29.8%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America32.8
- Europe21.1
- Asia Pacific22.1
- Latin America13.1
- Middle East and Africa11.0
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Swedish Orphan Biovitrum AB (Sobi) | 92 | 90 | 76 | 92 | 74 | 76 | 83 |
| Amgen Inc. | 68 | 71 | 69 | 81 | 86 | 76 | 75 |
| Horizon Therapeutics plc | 72 | 82 | 81 | 72 | 66 | 63 | 73 |
| Sandoz (a Novartis division) | 75 | 68 | 64 | 76 | 80 | 77 | 73 |
| Mylan N.V. (now part of Viatris) | 74 | 74 | 54 | 65 | 52 | 68 | 65 |
| Pfizer Inc. | 58 | 63 | 66 | 54 | 66 | 65 | 62 |
| AbbVie Inc. | 47 | 53 | 44 | 46 | 54 | 50 | 49 |
| Roche Holding AG | 50 | 38 | 38 | 46 | 56 | 51 | 47 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Swedish Orphan Biovitrum AB (Sobi)
- Amgen Inc.
- Horizon Therapeutics plc
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Swedish Orphan Biovitrum AB (Sobi) | ✓ | ✓ | ✓ | ◐ | ✓ | ◐ |
| Amgen Inc. | ◐ | ◐ | ◐ | ✓ | ◐ | ◐ |
| Horizon Therapeutics plc | ✓ | ✓ | ◐ | ◐ | ◐ | − |
| Sandoz (a Novartis division) | ◐ | ◐ | ◐ | ✓ | ◐ | ◐ |
| Mylan N.V. (now part of Viatris) | ✓ | ◐ | ◐ | ◐ | ◐ | ◐ |
| Pfizer Inc. | ◐ | ◐ | ✓ | ◐ | − | ◐ |
| AbbVie Inc. | − | ◐ | ◐ | ◐ | − | − |
| Roche Holding AG | ◐ | − | − | ◐ | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Swedish Orphan Biovitrum AB (Sobi)83
2Amgen Inc.75
3Horizon Therapeutics plc73
4Sandoz (a Novartis division)73
5Mylan N.V. (now part of Viatris)65
6Pfizer Inc.62
7AbbVie Inc.49
8Roche Holding AG47
Competitive tiers
§8.4 · p.172 →Leader1
Set the pace on share, breadth and innovation.
Swedish Orphan Biovitrum AB (Sobi)
Challenger3
Strong scale, closing on the leaders.
Amgen Inc.Horizon Therapeutics plcSandoz (a Novartis division)
Contender2
Focused players with pockets of strength.
Mylan N.V. (now part of Viatris)Pfizer Inc.
Niche2
Specialists in a single segment or region.
AbbVie Inc.Roche Holding AG
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Indication in North America, then scale across Anakinra Market — a $600M beachhead inside a $9.98B market.
Beachhead (SOM)$600Mobtainable near-term
Serviceable (SAM)$3.68Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale3 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion86 fit
Rheumatoid Arthritis
Best fit — highest urgency & budget in Indication.
Economic buyer78 fit
Cryopyrin-Associated Periodic Syndromes (CAPS)
Strong fit — clear ROI and a fast path to value.
End user68 fit
Systemic Juvenile Idiopathic Arthritis (SJIA)
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Indication in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Route of Administration & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales45%
Partner / channel28%
Digital / self-serve20%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Indication leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Anakinra Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified38%
Sales qualified23%
Evaluation13%
Closed-won6%
$14.3KCAC
$55KLTV
3.9:1LTV : CAC
< 5 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Anakinra Market is a high-growth opportunity — $8.66B by 2033, compounding at 10.7%.
TAM · 2025$3.84Btoday
TAM · 2033$8.66Bforecast
CAGR10.7%2027–2033
Cumulative$53.7Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$8.66BTotal addressable market
SAM$2.95BServiceable available market
SOM$625MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →10.7% CAGR
Demand compounds through 2033, outpacing GDP across Indication.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Indication moving from early to mainstream — durable secular demand.
Consolidation upside
10+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$8.66BLarge & growingTAM by 2033 at 10.7% CAGR
$2.95BServiceable nowreachable with today’s model
$625MBeachhead winobtainable near-term share
10+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$6.75BBear6.9% CAGR
$8.66BBase10.7% CAGR
$11.1BBull14.1% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Route of Administration optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Anakinra Market — a $1.52B market by 2033. Plan: grow share from 8.5% to 13.2%.
Market size · 2033$1.52Btotal addressable
Market CAGR3.4%2027–2033
Target share13.2%from 8.5% today
Revenue ambition$201Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 8.5% | 13.2% | Behind |
| Revenue | $136M | $201M | Ahead |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | At risk |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | At risk |
| Gross margin | 28.8% | 41.6% | At risk |
| Customer retention | 88.8% | 93.6% | Ahead |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Indication
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Route of Administration capability
A defensible second engine — invest in Route of Administration to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Indication share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Route of Administration
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $28M capacity & capability investment
- Greenlight bolt-on M&A in Route of Administration
- Authorise North America expansion plan
- Fund R&D program for Indication leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownBehind
- Competitive share lossBehind
- Input-cost & supply riskBehind
- Regulatory / policy changeBehind
- Execution & talentAhead
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Anakinra Market conversation — a $5.72B market you can size, segment and defend in minutes.
Market size · 2033$5.72Btotal opportunity
Growth7.5%CAGR to 2033
Addressable buyers1,068+accounts in scope
Typical ROI4.5×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Indication
Goal Grow share in Indication
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →4.5×return on cost, year one
< 3 mopayback period
$98K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
10+players profiled in this market
Coverage includes
Swedish Orphan Biovitrum AB (Sobi)Amgen Inc.Horizon Therapeutics plcSandoz (a Novartis division)Mylan N.V. (now part of Viatris)Pfizer Inc.AbbVie Inc.Roche Holding AG+2 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Anakinra Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Anakinra Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Dutasteride Market
Market size, share, segmentation and regional forecast.
$3.2B market · 2025 base year
View reportCemiplimab rwlc Market
Market size, share, segmentation and regional forecast.
$5.1B market · 2025 base year
View reportTildrakizumab Market
Market size, share, segmentation and regional forecast.
$559M market · 2025 base year
View reportBumetanide Tablets Market
Market size, share, segmentation and regional forecast.
$2.7B market · 2025 base year
View reportMultiple Sclerosis Drugs Market
Market size, share, segmentation and regional forecast.
$5.0B market · 2025 base year
View reportBudesonide Capsules Market
Market size, share, segmentation and regional forecast.
$5.7B market · 2025 base year
View reportTobramycin Eye Drop Market
Market size, share, segmentation and regional forecast.
$6.0B market · 2025 base year
View reportMedical X ray Market
Market size, share, segmentation and regional forecast.
$1.6B market · 2025 base year
View reportBudesonide Sprays Market
Market size, share, segmentation and regional forecast.
$3.9B market · 2025 base year
View reportEmergency Contraceptives Market
Market size, share, segmentation and regional forecast.
$3.8B market · 2025 base year
View reportRefined Cotton Based Microcrystalline Cellulose Market
Market size, share, segmentation and regional forecast.
$581M market · 2025 base year
View reportDipeptidyl Peptidase IV DPP IV Inhibitors Market
Market size, share, segmentation and regional forecast.
$5.5B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.